CriticalHMG-CoA reductase inhibitor (statin)×HIV protease inhibitor / pharmacokinetic booster
Updated · Methodology
Mechanism
The liver enzyme CYP3A4 clears lovastatin (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and ritonavir strongly inhibits the CYP3A enzymes (ritonavir SmPC, European Medicines Agency, EMA). Lovastatin levels are expected to rise sharply both at the treatment dose of ritonavir for human immunodeficiency virus (HIV) infection and at the low dose used to boost other antivirals (ritonavir SmPC, EMA). Itraconazole, another strong CYP3A4 inhibitor, raised lovastatin exposure (area under the curve, AUC) more than 36-fold. According to the US Food and Drug Administration (FDA) lovastatin label, this result may reflect the effect of HIV protease inhibitors. High lovastatin levels raise the risk of muscle damage (myopathy) and muscle breakdown (rhabdomyolysis) (ritonavir and lovastatin SmPCs, EMA and AEMPS).
Symptoms
Myopathy causes muscle pain, tenderness or weakness, with creatine kinase (CK) above ten times the upper limit of normal (lovastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In rhabdomyolysis, myoglobin from damaged muscle passes into the urine and can cause acute kidney failure, rarely fatal (lovastatin SmPC, AEMPS). Warning signs are unexplained muscle pain, tenderness or weakness, especially with malaise or fever (lovastatin label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated in the European Medicines Agency (EMA) summaries of product characteristics (SmPCs) of ritonavir, nirmatrelvir/ritonavir and lopinavir/ritonavir. It is also contraindicated in the lovastatin SmPC of the Spanish Agency of Medicines and Medical Devices (AEMPS), where human immunodeficiency virus (HIV) protease inhibitors appear among the contraindications, and in the US Food and Drug Administration (FDA) labels of ritonavir and lovastatin. The contraindication applies at any ritonavir dose: in HIV treatment and at the low dose used to boost another protease inhibitor. When ritonavir boosts another protease inhibitor, also check the SmPC of that drug (ritonavir SmPC, EMA). If the patient needs a statin, choose pravastatin or fluvastatin: their metabolism does not depend on CYP3A, and no interaction with ritonavir is expected (ritonavir SmPC, EMA). Simvastatin is also contraindicated with ritonavir. Give atorvastatin and rosuvastatin at the lowest dose and titrate them carefully (ritonavir SmPC, EMA; ritonavir FDA label). With lopinavir/ritonavir, atorvastatin is not recommended (lopinavir/ritonavir SmPC, EMA). If a patient taking lovastatin needs a short course of nirmatrelvir/ritonavir for COVID-19, stop lovastatin at least 12 hours before the first dose and do not give it during the 5 days of treatment or for 5 days after (nirmatrelvir/ritonavir FDA label). Ask the patient to report unexplained muscle pain, tenderness or weakness at once (lovastatin FDA label). If the patient has already taken both drugs and develops muscle pain, weakness or cramps, measure creatine kinase (CK). Stop lovastatin if CK is above 5 times the upper limit of normal or myopathy is suspected (lovastatin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Norvir (ritonavir) prescribing information (2026)– AbbVie. NORVIR (ritonavir) tablets, oral solution, oral powder. Prescribing information, DailyMed setid 2849298e-de6e-47bb-8194-56e075b33fc3, sections 4 and 7.2
- EMA: Ficha técnica: Ritonavir (EU/1/96/016), sección 4.3 (2026)– EMA, Norvir, ficha técnica en CIMA (nº registro 96016005), consultada 03.10.2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Nirmatrelvir/ritonavir (EU/1/22/1625), sección 4.3 (2026)– EMA, Paxlovid, ficha técnica en CIMA (nº registro 1221625001), consultada 03.10.2026, secciones 4.3 y 4.5
- FDA: PAXLOVID (nirmatrelvir; ritonavir) prescribing information (2026)– FDA, DailyMed setid 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a, revisión 02/2026 (versión 12), secciones 4 y 7.3
- AEMPS: Ficha técnica: Lovastatina (nº registro 63360), sección 4.3 (2023)– AEMPS, CIMA, nº registro 63360 (Lovastatina Cinfa 20 mg, Laboratorios Cinfa), documento 05/2023 (texto revisado 05/2023), secciones 4.3, 4.4 y 4.5; texto idéntico en Lovastatina Cinfa 40 mg (nº registro 63359)
- FDA: Lovastatin Tablets USP (lovastatin) prescribing information (2026)– FDA, DailyMed setid df7ddf4f-d569-431e-81f1-9129d7043150 (Lupin Pharmaceuticals), revisión 05/2026 (versión 17), Clinical Pharmacology (tabla I), Contraindications, Warnings (Myopathy/Rhabdomyolysis) y Precautions
- EMA: Ficha técnica: Lopinavir/ritonavir, Kaletra (EU/1/01/172), sección 4.3 (2026)– EMA, Kaletra 100 mg/25 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 01172006, consultada 18.10.2026, secciones 4.3 y 4.5